Genotyping and functional analysis of a polymorphic (CCTTT)n repeat of NOS2A in diabetic retinopathy

被引:128
作者
Warpeha, KM
Xu, W
Liu, L
Charles, IG
Patterson, CC
Ah-Fat, F
Harding, S
Hart, PM
Chakravarthy, U
Hughes, AE
机构
[1] Queens Univ Belfast, Dept Med Genet, Belfast, Antrim, North Ireland
[2] Queens Univ Belfast, Dept Epidemiol & Publ Hlth, Belfast, Antrim, North Ireland
[3] Royal Liverpool Hosp, Eye Unit, Liverpool L7 8XP, Merseyside, England
[4] UCL, Rayne Inst, Wolfson Inst Biomed Res, London, England
关键词
microvascular; transcription; NOS2A promoter; pentanucleotide repeat;
D O I
10.1096/fasebj.13.13.1825
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Accumulating evidence shows that the severity and rapidity of onset of diabetic retinopathy are influenced by genetic factors. Expression of the nitric oxide synthases is altered in the retinal vasculature in the early stages of diabetic retinopathy. We analyzed the allele distribution of a polymorphic pentanucleotide repeat within the 5' upstream promoter region of the NOS2A gene in samples of diabetic patients. In diabetic patients from Northern Ireland, the 14-repeat allele of the NOS2A marker was significantly associated with the absence of diabetic retinopathy. Carriers of this repeat had 0.21-fold the relative risk of developing diabetic retinopathy than noncarriers of this allele. They also had significantly fewer renal and cardiovascular complications. The ability of differing numbers of (CCTTT)(n) pentanucleotide repeats to induce transcription of the NOS2A gene was analyzed using a luciferase reporter gene assay in transfected colonic carcinoma cells. Interleukin 1b (IL-1b) induction was most effective in constructs carrying the 14-repeat allele. When cells were incubated in 25 mM glucose to mimic the diabetic state, IL-1 beta induction was inhibited in all cases, but to a significantly lesser extent with the 14-repeat allele. These unique properties of the 14-repeat allele may confer selective advantages in diabetic individuals, which may delay or prevent microvascular complications of diabetes.
引用
收藏
页码:1825 / 1832
页数:8
相关论文
共 38 条
[1]   HLA-DQB1*0201/0302 is associated with severe retinopathy in patients with IDDM [J].
Agardh, D ;
Gaur, LK ;
Agardh, E ;
LandinOlsson, M ;
Agardh, CD ;
Lernmark, A .
DIABETOLOGIA, 1996, 39 (11) :1313-1317
[2]   IDENTIFICATION OF MULTIPLE GENES IN BOVINE RETINAL PERICYTES ALTERED BY EXPOSURE TO ELEVATED LEVELS OF GLUCOSE BY USING MESSENGER-RNA DIFFERENTIAL DISPLAY [J].
AIELLO, LP ;
ROBINSON, GS ;
LIN, YW ;
NISHIO, Y ;
KING, GL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (13) :6231-6235
[3]  
[Anonymous], 1981, INVEST OPHTH VIS SCI, V21, P210
[4]  
Chakravarthy U, 1997, INVEST OPHTH VIS SCI, V38, P2144
[5]   Constitutive nitric oxide synthase expression in retinal vascular endothelial cells is suppressed by high glucose and advanced glycation end products [J].
Chakravarthy, U ;
Hayes, RG ;
Stitt, AW ;
McAuley, E ;
Archer, DB .
DIABETES, 1998, 47 (06) :945-952
[6]   Endothelial cells in culture: An experimental model for the study of vascular dysfunctions [J].
Chappey, O ;
Wautier, MP ;
Boval, B ;
Wautier, JL .
CELL BIOLOGY AND TOXICOLOGY, 1996, 12 (4-6) :199-205
[7]   CLONING, CHARACTERIZATION, AND EXPRESSION OF A CDNA-ENCODING AN INDUCIBLE NITRIC-OXIDE SYNTHASE FROM THE HUMAN CHONDROCYTE [J].
CHARLES, IG ;
PALMER, RMJ ;
HICKERY, MS ;
BAYLISS, MT ;
CHUBB, AP ;
HALL, VS ;
MOSS, DW ;
MONCADA, S .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (23) :11419-11423
[8]   RETINAL VASCULAR PATTERNS .4. DIABETIC RETINOPATHY [J].
COGAN, DG ;
KUWABARA, T ;
TOUSSAINT, D .
ARCHIVES OF OPHTHALMOLOGY, 1961, 66 (03) :366-&
[9]   Transcriptional regulation of human inducible nitric oxide synthase (NOS2) gene by cytokines: Initial analysis of the human NOS2 promoter [J].
deVera, ME ;
Shapiro, RA ;
Nussler, AK ;
Mudgett, JS ;
Simmons, RL ;
Morris, SM ;
Billiar, TR ;
Geller, DA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (03) :1054-1059
[10]  
Diabet Control Complications Trial Res Grp, 1997, DIABETES, V46, P1829